To evaluate the frequency and cytogenetic and immunophenotypic features of therapy-related, precursor B-cell acute lymphoblastic leukemia (ALL), 152 cases of immature B-cell ALL were reviewed. These were compared to the frequency of therapy-related acute myeloid leukemia (t-AML) during the same time period. Eight ALL cases with a prior diagnosis of malignancy were identified, including six (4.0%) with prior therapy considered to be therapy-related ALL (t-ALL). The t-ALL cases followed treatment for breast carcinoma (two cases), lung carcinoma (two cases), lymphocyte predominance Hodgkin's disease and follicular lymphoma with a latency period of 13 months to 8 years. All t-ALL cases had a pro-B (CD10-negative) immunophenotype with significantly higher expression of CD15 and CD65, compared to the de novo CD10-positive ALL cases. All six t-ALL cases had MLL abnormalities by fluorescence in situ hybridization, and four showed t(4;11)(q21;q23). These represented half of all 11q23-positive adult ALL cases. During the same time period, 4.9% of all AML cases were considered t-AML. There was a 16.7% frequency of 11q23 abnormalities in the t-AML group. Despite the similar frequency in therapy-related disease among ALL and AML cases, there were differences in the frequency of the diseases and t-ALL represented 12% of all therapy-related leukemias. However, t-ALL represented 46% of all 11q23-positive therapyrelated leukemias. The immunogenetic features of t-ALL appear distinct and may aid in identifying more cases of this disease type in the future.
Introduction
The successful treatment of many malignancies with chemotherapy and radiation therapy has resulted in the long-term survival and cure of many patients. However, this success has been accompanied by the realization that a subset of these patients will ultimately develop a second malignancy. Second malignancies after therapy include both solid tumors and leukemias. [1] [2] [3] [4] Of the leukemias, therapy-related myelodysplasia and acute myeloid leukemia (AML) are most often reported. Differences in the treatment regimens used for the primary tumors are now recognized to result in clinical and cytogenetic differences in these therapy-related leukemias. 5 Patients treated with alkylating agents more commonly have a longer time interval between the primary tumor and leukemia and are associated with unbalanced abnormalities of chromosomes 5 and/or 7. In contrast, topoisomerase II inhibitor-related leukemia is associated with a shorter latency period and more frequent balanced cytogenetic abnormalities that commonly involve chromosome region 11q23 (site of the MLL gene), and less commonly 22q22 (site of the AML1 gene). The combined use of chemotherapy and radiation therapy in bone marrow transplantation is reportedly associated with a 3-8% long-term risk of developing a secondary solid tumor and a 1-3% long-term risk of developing AML or myelodysplasia. 2 Clonal cytogenetic abnormalities, even in the absence of disease, occur in as many as 9% of patients after autologous bone marrow transplantation. 6 Therapy-related acute lymphoblastic leukemia (t-ALL) is much less common than therapy-related AML and myelodsyplasia, with only a small number of total cases reported in the literature. [7] [8] [9] In one series, t-ALL represented 1.2% of ALL cases. This rare leukemia type is associated with 11q23 abnormalities in most, but not all, reports. The current study was designed to determine the frequency of therapy-related precursor B-cell ALL in adult patients at a single institution, and to determine the immunophenotypic and cytogenetic features of this disease. The frequency of t-ALL was also compared to t-AML during the same time period.
Materials and methods
All cases of precursor B-cell ALL with immunophenotyping performed at the City of Hope National Medical Center between February 1989 and April of 2001 were reviewed. Of these, 152 cases were identified in patients 18 years of age or older, which included 82 newly diagnosed and 70 with relapsed ALL that were originally diagnosed at 18 years of age or older. Of these, available immunophenotyping and genetic studies were reviewed for each case. Immunophenotyping studies were primarily performed by flow cytometry, as previously described. 10 Flow cytometry immunophenotyping studies were compared between the pro-B and nonpro-B precursor B (CD10+) ALL group. Blasts were considered positive if 20% or more expressed an antigen. Blasts were initially gated for analysis by using forward vs side scatter, and since 1995, by using CD45 antigen expression and right-angle light scatter. The number of antibodies used varied, with fewer studies performed on the older cases. Some results were determined by immunohistochemistry, using previously described methods. 11 A cutoff of 20% or greater for a positive interpretation was also used for the immunohistochemical studies.
Cytogenetic analysis was performed on peripheral blood or bone marrow specimens using standard techniques. GTG banding was used to identify the individual chromosomes. When available, at least 20 metaphases were examined from each case. Cytogenetic nomenclature followed standard ISCN 1995 criteria. 12 RNA was extracted from peripheral blood or bone marrow aspirate cells and analyzed using the reverse transcriptase polymerase chain reaction (RT-PCR) technique designed to detect both the p210 and p190 bcr/abl fusion transcripts of the (9;22) translocation, as previously described. 13 For fluorescence in situ hybridization (FISH) studies for BCR/ ABL and MLL rearrangements, chromosome spreads were prepared by standard methods. Slides were incubated in 2 Â SSC at 371C for 30 min, denatured in 70% formamide/2 Â SSC (pH 7.0) at 721C for 2 min. Slides were hybridized using MLL breakapart and BCR/ABL single fusion probes (Vysis, Inc., Downer's Grove, IL, USA). A volume of 5 mL of probe was heat denatured at 721C for 5 min, applied to denatured slides and covered with a 18 mm round coverslip sealed with rubber cement. Slides were incubated in a humidified chamber at 371C overnight. Nonspecific probe binding was removed by a 0.4 Â SSC/0.3% Nonidet P40 (pH 7.0) posthybridization wash at 721C for 2 min, followed by 2 Â SSC/0.1% NP40 (pH7.0) at room temperature for 1 min. Cells were counterstained with 4 0 6 0 -diamino-2 phenyl indole dihydrochloride (Vysis, Inc.). Lymphocytes from a phenotypically normal female were used as a negative control. In all, 200 nuclei were scored for each probe combination and each patient. Using the single fusion BCR/ABL probe, in-house validation studies indicated that samples with greater than 6% positive cells had a BCR/ABL gene rearrangement [sensitivity 95.2% (95% confidence interval (CI) ¼ 76.2-99.9%) and specificity 100% (95% CI ¼ 82.4-100%)]. Samples were considered positive for an MLL rearrangement if greater than 3% of the interphase nuclei scored were positive [sensitivity 100% (95% CI ¼ 80.5-100%) and specificity 100% (95% CI ¼ 71.5-100%)] (Figure 1 ). w 2 analysis was used for statistical comparison. A history of prior therapy was determined by chart reviews and Cancer Registry data, and such data were available for 150 ALL patients. The incidence of t-AML diagnosed during the same time period at the City of Hope was also determined by a search of the City of Hope Cancer Registry and chart reviews. The City of Hope Institutional Review Board and Cancer Protocol Review & Monitoring Committee (#95124) approved the study.
Results
Eight of the 150 adult precursor B-cell ALL patients with available data had a known history of prior malignancy with six (4.0%) of them treated with chemotherapy and/or radiotherapy, consistent with therapy-related disease (t-ALL) ( Table 1 ). The t-ALL cases showed a 2: 4 male-to-female ratio, with a median/ mean age of 59.5/53.7 years (range 25-69 years) ( Table 2 ). The remaining ALL cases had a median/mean age of 36/37.2 years (range 18-81 years) and included 89 males and 57 females. The t-ALL cases included two patients with prior breast carcinoma, two with prior lung carcinoma, and one each with follicular lymphoma and recurrent lymphocyte predominance Hodgkin's disease. The two other patients with prior tumors included one patient with malignant melanoma and one with a poorly defined oral malignancy, and both were treated with wide local excision alone. Of the six patients with t-ALL, four received drugs that cause topoisomerase II-dependent DNA cleavage, one was treated with only radiation therapy and details of the chemotherapy for one patient were not available. The latency period could be determined for four of the cases and ranged from 13 to 96 months. Of the four patients with adequate follow-up, two were dead of disease at 0.4 and 13.9 months and two were alive with no evidence of disease at 21 and 54 months.
All t-ALL cases were CD10-negative (pro-B immunophenotype), and these represented 35% (six of 17) of all pro-B ALLs in the study. Although a general cutoff of 20% was used for CD10 expression, all cases of t-ALL had less than 5% CD10-positive cells. These therapy-related pro-B ALL cases significantly differed from the remaining CD10-positive ALL cases by their aberrant expression of CD15 (five of six cases) and CD65 (three of three cases) and by their decreased expression of CD34 (two of six cases) ( Table 3) . No aberrant expression of CD13 or CD33 was identified in this group. Similar differences in the expression of CD15, CD65 and CD34 were observed when all pro-B ALL cases were compared to CD10-positive ALLs, but no significant differences in the immunophenotype of t-ALL cases vs the other pro-B ALL cases was identified (data not shown).
All six t-ALL cases had 11q23/MLL abnormalities with four showing t(4;11)(q21;q23) by karyotype analysis, one showing an unbalanced 11q23 abnormality and one with only FISH analysis ( Table 4) . Involvement of the MLL gene was confirmed by FISH in all cases. Six additional ALL cases with 11q23 abnormalities were present in the cohort, including three that had FISH studies to confirm involvement of the MLL gene. These included five cases with a pro-B ALL immunophenotype and one CD10-a b Figure 1 Representative signal patterns using the Vysis MLL dual color FISH. Panel A demonstrates the typical dual fusion signal pattern found in cases with normal intact MLL genes. In these cases, a fusion (red/green) signal is seen on each 11 chromosome (arrows). Panel B demonstrates the typical signal pattern obtained when the MLL gene is rearranged. In these cases, a fusion (red/green) signal represents an intact MLL gene, whereas separated red and green signals (arrows) represent an MLL rearrangement. Other antigens evaluated that showed no significant difference between disease groups included CD2, CD3, CD4, CD5, CD7, CD8, CD14, CD19, CD56, CD61, CD117, glycophorin, HLA-DR and TdT.
Therapy-related ALL S Ishizawa et al therapy-related leukemias. Of the therapy-related leukemias, 27% (13 of 48) had 11q23 abnormalities, of which 46% (six of 13) were t-ALL.
Discussion
Acute leukemia secondary to prior therapy may be of myeloid or lymphoblastic lineage, but AML is most common. The current study, however, suggests that t-ALL is more common than previously thought, representing 12% of all therapy-related leukemias in one institution. In a recent international study of 511 therapy-related acute leukemias and myelodysplastic syndromes with balanced chromosome aberrations, only 20 (3.9%) cases were t-ALLs. 5 The GIMEMA (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto) Archive of Adult Acute Leukemia retrospectively identified 21 cases of ALL in patients with prior malignancy, representing 2.3% of all ALL cases. 7 Of those cases, only 11 (1.2% of all cases) received prior chemotherapy or radiation therapy. The reason for the discrepancy in the incidence of t-ALL between these previous reports and the current study is not clear, but suggests that t-ALL may have been underrecognized in prior studies. Histories of prior therapy may not be pursued as aggressively in patients with ALL as they are in AML because of lack of recognition of the possibility of therapy-related disease in ALL. The chart reviews of some of the t-ALL patients in the current study revealed that the physician treating the patient for ALL did not appear to recognize a possible link between the patients' prior malignancy and the later development of ALL.
It is now clear that many therapy-related leukemias have rearrangements of the MLL gene and such rearrangements are highly associated with prior topoisomerase II inhibitor therapy. The current study and others, however, suggest that MLL abnormalities are involved in a higher percentage of t-ALL cases than t-AML cases, and t-ALL is usually associated with t(4;11). 8, 9, [14] [15] [16] Andersen et al 8 recently reported two cases of MLL-positive, t-ALL and identified 21 other cases in the literature. All of those previously reported cases had received at least one topoisomerase II inhibitor. In an international workshop focusing on 11q23 abnormalities, 16 7.3% of patients had secondary leukemia or myelodysplasia and 22.5% (nine of 40) had ALL. Eight had t(4;11) and one showed t(1;11)(q21;q23). This study showed a latency period for developing 11q23-associated t-ALL ranging from 12 months to 22 years with a median latency of 16 months. The six t-ALL cases in the current study all demonstrated evidence of MLL rearrangements, and four showed t(4;11). The latency period for the development of t-ALL ranged from 13 months to 8 years. In contrast to most previous reports, one patient in the current study with a history of breast cancer did not receive chemotherapy and was only treated with radiation therapy to the breast. However, therapyrelated leukemia with 11q23 abnormalities has been reported following radiation therapy alone, with five cases included in a recent report by Bloomfield et al. 9 Not all reports of t-ALL, however, have such a prominent association with 11q23/MLL rearrangements. In the GIMEMA study of t-ALL, 7 karyotype results were evaluable for 16 patients and only one had an 11q23 abnormality.
The immunophenotypic features of precursor B-cell t-ALL also appears to be unique when compared to other adult ALLs, and is similar to MLL-positive infant ALL. All of the t-ALL cases in the current study had a CD10-negative, pro-B immunophenotype and there was significant aberrant coexpression of CD15 and CD65 in these cases. Prior studies have confirmed the correlation between lack of CD10 expression in ALL with aberrant CD15 and CD65 expression and MLL rearrangements in both adults and infants. [17] [18] [19] [20] Other similarities between infant pro-B ALL and therapy-related leukemia have also been described. Cimino et al 21 analyzed the specific breakpoints in the MLL gene in infant leukemias, de novo leukemias and topoisomerase II inhibitor-related leukemias, and found similarities in gene breakpoints between the infant and therapy-related group that was not found in the de novo leukemia group. This finding suggests a similar mechanism of leukemogenesis in the two groups.
The current study also attempted to compare the frequency of t-ALL to t-AML in a single institution. Although therapy-related disease represented 4.0 and 4.9% of all ALL and AML cases, respectively, AML was much more common and t-AML represented 88% of all therapy-related leukemia during the time period of the study. In contrast, therapy-related 11q23 abnormalities were similar in the two groups with seven cases identified in the t-AML group and six in the t-ALL group. Therefore, in the setting of therapy-related 11q23 abnormalities, there is a similar frequency in the development of ALL as AML. While t-ALL remains a relatively uncommon disease, the current findings suggest clues to the identification of such cases. Adult ALL with a pro-B cell immunophenotype and aberrant expression of CD15 or CD65 should warrant cytogenetic and possibly molecular genetic investigation for an 11q23 abnormality. Identification of such an 11q23 abnormality, especially t(4;11), should raise suspicions for therapy-related disease. A relation between prior therapy and ALL may have been unappreciated and significantly underestimated in prior studies. Recognition of this immunogenetic phenotype may result in an increased appreciation of t-ALL.
